Survival analysis of the RNA microarray database predicted that the “High Risk” group of patients with AML presented a significantly higher PRDM5 expression level and had a poorer prognosis than the “Low Risk” group (Figure 1B). This evidence concerns the gene PRDM5 and acute myeloid leukemia.